Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Alterations of specific chromatin conformation affect ATRA-induced leukemia cell differentiation.

Li Y, He Y, Liang Z, Wang Y, Chen F, Djekidel MN, Li G, Zhang X, Xiang S, Wang Z, Gao J, Zhang MQ, Chen Y.

Cell Death Dis. 2018 Feb 8;9(2):200. doi: 10.1038/s41419-017-0173-6.

2.

Lentivirus-mediated RNA interference targeting FAMLF-1 inhibits cell growth and enhances cell differentiation of acute myeloid leukemia partially differentiated cells via inhibition of AKT and c-MYC.

Huang YM, Zheng Y, Li JG, Wang XC, Wang ZC, Chen WL, Pan LL, Li Y, Luo DF, Wang SY.

Oncotarget. 2017 Sep 26;8(60):101372-101382. doi: 10.18632/oncotarget.21276. eCollection 2017 Nov 24.

3.

Hoxa9 and Hoxa10 induce CML myeloid blast crisis development through activation of Myb expression.

Negi V, Vishwakarma BA, Chu S, Oakley K, Han Y, Bhatia R, Du Y.

Oncotarget. 2017 Oct 24;8(58):98853-98864. doi: 10.18632/oncotarget.22008. eCollection 2017 Nov 17.

4.

B-cell identity as a metabolic barrier against malignant transformation.

Chan LN, Müschen M.

Exp Hematol. 2017 Sep;53:1-6. doi: 10.1016/j.exphem.2017.06.004. Epub 2017 Jun 24. Review.

PMID:
28655536
5.

Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes.

Chong CE, Venugopal P, Stokes PH, Lee YK, Brautigan PJ, Yeung DTO, Babic M, Engler GA, Lane SW, Klingler-Hoffmann M, Matthews JM, D'Andrea RJ, Brown AL, Hahn CN, Scott HS.

Leukemia. 2018 Jan;32(1):194-202. doi: 10.1038/leu.2017.196. Epub 2017 Jun 23.

6.

GATA2 deficiency and related myeloid neoplasms.

Wlodarski MW, Collin M, Horwitz MS.

Semin Hematol. 2017 Apr;54(2):81-86. doi: 10.1053/j.seminhematol.2017.05.002. Epub 2017 May 10.

7.

The GATA factor revolution in hematology.

Katsumura KR, Bresnick EH; GATA Factor Mechanisms Group.

Blood. 2017 Apr 13;129(15):2092-2102. doi: 10.1182/blood-2016-09-687871. Epub 2017 Feb 8. Review.

8.

GATA factor mutations in hematologic disease.

Crispino JD, Horwitz MS.

Blood. 2017 Apr 13;129(15):2103-2110. doi: 10.1182/blood-2016-09-687889. Epub 2017 Feb 8. Review.

9.

GATA Factor-Dependent Positive-Feedback Circuit in Acute Myeloid Leukemia Cells.

Katsumura KR, Ong IM, DeVilbiss AW, Sanalkumar R, Bresnick EH.

Cell Rep. 2016 Aug 30;16(9):2428-41. doi: 10.1016/j.celrep.2016.07.058. Epub 2016 Aug 18.

10.

HBV suppresses expression of MICA/B on hepatoma cells through up-regulation of transcription factors GATA2 and GATA3 to escape from NK cell surveillance.

Guan Y, Li W, Hou Z, Han Q, Lan P, Zhang J, Tian Z, Zhang C.

Oncotarget. 2016 Aug 30;7(35):56107-56119. doi: 10.18632/oncotarget.11271.

11.

The emerging role of GATA transcription factors in development and disease.

Lentjes MH, Niessen HE, Akiyama Y, de Bruïne AP, Melotte V, van Engeland M.

Expert Rev Mol Med. 2016 Mar 8;18:e3. doi: 10.1017/erm.2016.2. Review.

12.

Isolated Ocular Manifestation of Relapsed Chronic Myelogenous Leukemia Presenting as Myeloid Blast Crisis in a Patient on Imatinib Therapy: A Case Report and Review of the Literature.

Gulati R, Alkhatib Y, Donthireddy V, Felicella MM, Menon MP, Inamdar KV.

Case Rep Pathol. 2015;2015:380451. doi: 10.1155/2015/380451. Epub 2015 Dec 24.

13.

GATA family transcriptional factors: emerging suspects in hematologic disorders.

Gao J, Chen YH, Peterson LC.

Exp Hematol Oncol. 2015 Oct 6;4:28. doi: 10.1186/s40164-015-0024-z. eCollection 2015. Review.

14.

GATA2 rs2335052 Polymorphism Predicts the Survival of Patients with Colorectal Cancer.

Liu X, Jiang B, Wang A, Di J, Wang Z, Chen L, Su X.

PLoS One. 2015 Aug 19;10(8):e0136020. doi: 10.1371/journal.pone.0136020. eCollection 2015.

15.

GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies.

Wang X, Muramatsu H, Okuno Y, Sakaguchi H, Yoshida K, Kawashima N, Xu Y, Shiraishi Y, Chiba K, Tanaka H, Saito S, Nakazawa Y, Masunari T, Hirose T, Elmahdi S, Narita A, Doisaki S, Ismael O, Makishima H, Hama A, Miyano S, Takahashi Y, Ogawa S, Kojima S.

Haematologica. 2015 Oct;100(10):e398-401. doi: 10.3324/haematol.2015.127092. Epub 2015 May 28. No abstract available.

16.

Haematopoietic and immune defects associated with GATA2 mutation.

Collin M, Dickinson R, Bigley V.

Br J Haematol. 2015 Apr;169(2):173-87. doi: 10.1111/bjh.13317. Epub 2015 Feb 23. Review.

17.

A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

Vidal SJ, Rodriguez-Bravo V, Quinn SA, Rodriguez-Barrueco R, Lujambio A, Williams E, Sun X, de la Iglesia-Vicente J, Lee A, Readhead B, Chen X, Galsky M, Esteve B, Petrylak DP, Dudley JT, Rabadan R, Silva JM, Hoshida Y, Lowe SW, Cordon-Cardo C, Domingo-Domenech J.

Cancer Cell. 2015 Feb 9;27(2):223-39. doi: 10.1016/j.ccell.2014.11.013.

18.

Spectrum of myeloid neoplasms and immune deficiency associated with germline GATA2 mutations.

Mir MA, Kochuparambil ST, Abraham RS, Rodriguez V, Howard M, Hsu AP, Jackson AE, Holland SM, Patnaik MM.

Cancer Med. 2015 Apr;4(4):490-9. doi: 10.1002/cam4.384. Epub 2015 Jan 26. Review.

19.

Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.

Eiring AM, Deininger MW.

Genome Biol. 2014 Sep 17;15(9):461. doi: 10.1186/s13059-014-0461-8. Review.

20.

Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature.

Gao J, Gentzler RD, Timms AE, Horwitz MS, Frankfurt O, Altman JK, Peterson LC.

J Hematol Oncol. 2014 Apr 22;7:36. doi: 10.1186/1756-8722-7-36. Review. Erratum in: J Hematol Oncol. 2015;8:131.

Supplemental Content

Support Center